Literature DB >> 8940110

The deletion of 14 amino acids in the seventh transmembrane domain of a naturally occurring calcitonin receptor isoform alters ligand binding and selectively abolishes coupling to phospholipase C.

J F Shyu1, D Inoue, R Baron, W C Horne.   

Abstract

The cDNA that encodes the rabbit calcitonin receptor was cloned by screening a rabbit osteoclast library. Reverse transcription-polymerase chain reaction amplification of calcitonin receptor sequences from rabbit osteoclast RNA yielded cDNAs that encode two isoforms of the calcitonin receptor. One isoform is homologous to the C1a isoform previously identified in multiple cell types and species, while the second, designated CTRDeltae13, is a previously unidentified isoform that is apparently generated by alternative splicing during mRNA processing that deletes exon 13, resulting in the absence of 14 amino acids in the predicted seventh transmembrane domain. Expression of mRNA transcripts encoding the two isoforms varies in a tissue-specific manner, with CTRDeltae13 accounting for less than 15% of the total calcitonin receptor mRNA in osteoclasts, kidney, and brain, but comprising at least 50% of the transcripts in skeletal muscle and lung. The two isoforms were expressed, and the ligand binding and signal transduction properties were characterized. Deletion of the residues in the seventh transmembrane domain in CTRDeltae13 reduced the binding affinity for salmon and human calcitonin by more than 10-fold and approximately 2-fold, respectively, resulting in a receptor that failed to discriminate between the two forms of calcitonin. Both isoforms activated adenylyl cyclase, with EC50 values consistent with the difference in ligand affinities. In contrast, only the C1a isoform, but not the CTRDeltae13 isoform, activated phospholipase C. Thus, while the CTRDeltae13 remains active despite the deletion of a significant portion of its seventh transmembrane domain, it has significantly altered ligand recognition and signal transduction properties.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940110     DOI: 10.1074/jbc.271.49.31127

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Calcitonin and calcitonin receptors: bone and beyond.

Authors:  M Pondel
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

2.  The delta e13 isoform of the calcitonin receptor forms a six-transmembrane domain receptor with dominant-negative effects on receptor surface expression and signaling.

Authors:  Thomas Seck; Maria Pellegrini; Ana Maria Florea; Veronique Grignoux; Roland Baron; Dale F Mierke; William C Horne
Journal:  Mol Endocrinol       Date:  2005-04-28

3.  Calpain is required for normal osteoclast function and is down-regulated by calcitonin.

Authors:  Marilena Marzia; Riccardo Chiusaroli; Lynn Neff; Na-Young Kim; Athar H Chishti; Roland Baron; William C Horne
Journal:  J Biol Chem       Date:  2006-02-03       Impact factor: 5.157

Review 4.  Emerging role of alternative splicing of CRF1 receptor in CRF signaling.

Authors:  Michał A Zmijewski; Andrzej T Slominski
Journal:  Acta Biochim Pol       Date:  2010-03-16       Impact factor: 2.149

5.  Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice.

Authors:  Rachel A Davey; Andrew G Turner; Julie F McManus; W S Maria Chiu; Francisca Tjahyono; Alison J Moore; Gerald J Atkins; Paul H Anderson; Cathy Ma; Vaida Glatt; Helen E MacLean; Cristina Vincent; Mary Bouxsein; Howard A Morris; David M Findlay; Jeffrey D Zajac
Journal:  J Bone Miner Res       Date:  2008-08       Impact factor: 6.741

6.  The elevated expression of calcitonin receptor by cells recruited into the endothelial layer and neo-intima of atherosclerotic plaque.

Authors:  Peter J Wookey; Anthony Zulli; David L Hare
Journal:  Histochem Cell Biol       Date:  2009-04-29       Impact factor: 4.304

Review 7.  Molecular regulation of osteoclast activity.

Authors:  Angela Bruzzaniti; Roland Baron
Journal:  Rev Endocr Metab Disord       Date:  2006-06       Impact factor: 9.306

8.  A naturally occurring isoform inhibits parathyroid hormone receptor trafficking and signaling.

Authors:  Verónica Alonso; Juan A Ardura; Bin Wang; W Bruce Sneddon; Peter A Friedman
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

9.  Alternative Splicing of the Pituitary Adenylate Cyclase-Activating Polypeptide Receptor PAC1: Mechanisms of Fine Tuning of Brain Activity.

Authors:  Janna Blechman; Gil Levkowitz
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-21       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.